Abstract:Background In the TARGET I randomized controlled trial, the novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent FIREHAWK proved non-inferior to the everolimus-eluting stent in nine-month in-stent late loss in single de novo coronary lesions. This study was aimed at evaluating clinical safety and effectiveness of FIREHAWK in a moderately complex population (including patients with small vessels, long lesions and multi-vessels), and at validating the ability of the SYNTAX score (SS) to predict clinical outcomes in patients treated with this latest generation drug-eluting stent.Methods TARGET II was a prospective, multicenter, single-arm study with primary outcome of 12-month target lesion failure (TLF), including cardiac death, target vessel myocardial infarction (TV-MI) and ischemia-driven target lesion revascularization (TLR). Stent thrombosis was defined according to the Academic Research Consortium (ARC) definition. Patients were grouped by tertiles of SS (<= 6, >6 to <= 12, and >12). All patients were exclusively treated with the FIREHAWK stent and were followed up at 1, 6, and 12 months, and annually thereafter up to five years.Results A total of 730 patients were included in this registry study. The 12-month incidence of TLF was 4.4% and the incidence of TLF components were, cardiac death 0.5%, TV-MI 3.2%, and TLR 2.2%. One definite/probable stent thrombosis was observed at 12-month follow-up. Mean SS was 10.87 +/- 6.87. Patients in the SS >12 tertile had significantly higher TLF (P=0.02) and TLR (P <0.01) rates than those in lower SS groups. In COX proportional-hazards regression analyses, TLF incidence was strongly related to lesion length (long lesion vs. non-long lesion patients; HR 3.416, 95% CI, 1.622-7.195), but unrelated to diabetic, small vessel, and multivessel subgroups.Conclusions The low TLF incidence in this study indicates that FIREHAWK is safe and effective in the treatment of moderately complex coronary disease. SS is also able to predict adverse clinical outcomes in FIREHAWK treated patients.

One-year Clinical Results of the NANO Registry: A Multicenter, Prospective All-Comers Registry Study in Patients Receiving Implantation of a Polymer-Free Sirolimus-Eluting Stent.

Clinical Outcomes in 2481 Unselected Real-World Patients Treated with a Polymer-Free Sirolimus-Eluting Stent: 3 Years Results from the NANO Multicenter Registry

Three‐year Clinical Outcomes of the Novel Sirolimus‐eluting Bioresorbable Scaffold for the Treatment of De Novo Coronary Artery Disease: A Prospective Patient‐level Pooled Analysis of NeoVas Trials

Nine-month Angiographic and Two-Year Clinical Follow-Up of Polymer-Free Sirolimus-Eluting Stent Versus Durable-Polymer Sirolimus-Eluting Stent for Coronary Artery Disease: the Nano Randomized Trial.

A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial

Safety and Efficacy of the Cypher Select Sirolimus-Eluting Stent in the "real World" - Clinical and Angiographic Results from the China Cypher Select Registry

Clinical effect of polymer-free sirolimus-eluting Nano stent on patients with coronary artery stenosis

A novel biodegradable polymer-coated sirolimus-eluting stent: the 1-year results of the HELIOS registry

Design and Rationale of Targeted Therapy With a Sirolimus-Eluting, Biodegradable Polymer Coronary Stent in Chronic Total Occlusions (TARGET CTO): A Multicenter, Open-Label, Randomized Noninferiority Trial.

Safety and efficacy of polymer-free paclitaxel-eluting microporous stent in real-world practice: 1-year follow-up of the SERY-I registry.

Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 12-Month Results from the TARGET II Trial.

A Novel Biodegradable Polymer-Coated Sirolimus-Eluting Stent: 1-Year Results of the HELIOS Registry.

Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the NOYA I trial.

Open-labeled randomized controlled trial to evaluate the 1-year clinical outcomes of polymer-free sirolimus-eluting coronary stents as compared with biodegradable polymer-based sirolimus-eluting coronary stents

One-year Clinical Outcomes and Multislice Computed Tomography Angiographic Results Following Implantation of the NeoVas Bioresorbable Sirolimus-Eluting Scaffold in Patients with Single De Novo Coronary Artery Lesions

Clinical and multimodality imaging results at 6 months of a bioresorbable sirolimus-eluting scaffold for patients with single de novo coronary artery lesions: the NeoVas first-in-man trial.

Three-Year Clinical Outcomes of a Polymer-Free Paclitaxel-Eluting Microporous Stent in Real-World Practice: Final Results of the Safety and Efficacy Registry of the Yinyi Stent (SERY-I).

TCT-430 Nine-Month Angiographic and 1-Year Clinical Outcomes of the RECOVERY Study: A Randomized Trial Evaluating the Safety and Efficacy of the Combo Bio-Engineered Sirolimus-Eluting Stent Versus the Nano Polymer-Free Sirolimus-Eluting Stent in Patients with Coronary Artery Disease

AS-023: Efficacy and Safety of a Novel Non-Symmetrical, Biodegradable Polymer-Coated Sirolimus-Eluting Stent in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

One-year Outcomes from an All-Comers Chinese Population of Patients Implanted with the Resolute Zotarolimus-Eluting Stent.